Alessi. McManus, Sakamoto, Alessi, and colleagues created a genetically modified homozygous mouse model in which the two endogenous GSK-3 genes had been eliminated and replaced, through gene knockin (KI), by corresponding genes encoding mutations at the NH 2 -terminal phosphorylation sites [from serine to alanine residues (2)]. The clear advantage of such a model is the complete replacement of the wild-type kinases with constitutively active forms whose expression is transcriptionally regulated by the wild-type GSK-3 gene promoters.
Sakamoto and colleagues [Bouskila et al. (1)] now took advantage of that mouse model to show that, compared with wild-type littermates, muscles from these KI mice have similar glycogen content in the fasted and fed state or following a bolus injection of glucose, despite lack of insulin-stimulated glycogen synthase activity. The muscles from the KI mice also had similar rates of glycogen accumulation compared with controls 1 or 2 h after exposure to insulin in vitro. As well, insulin increased normally both glucose transport and glucose 6-phosphate levels in KI mice. Furthermore, KI mice did not have compensatory alterations in glycogen metabolism muscle phosphorylase activity and responded normally to epinephrine by inhibition of glycogen synthase and stimulation of glycogen phosphorylase. The authors suggest, by extrapolation of the results, that glucose 6-phosphate may be the major regulator of insulin-stimulated glycogen accumulation. This is an intriguing proposition that will likely elicit further direct analysis, a challenge that Kei Sakamoto contemplates, probably along with many of our reader experts in this area.
We are pleased to highlight the work of this young scientist and hope that it will inspire young investigators in pursuit of the intricacies of endocrinology and metabolism.
